{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T09:52:31Z","timestamp":1760953951012},"reference-count":40,"publisher":"The Endocrine Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,8,1]]},"DOI":"10.1210\/jc.2016-4025","type":"journal-article","created":{"date-parts":[[2017,5,26]],"date-time":"2017-05-26T18:04:33Z","timestamp":1495821873000},"page":"2922-2929","source":"Crossref","is-referenced-by-count":16,"title":["Sorafenib-Induced Changes in Thyroid Hormone Levels in Patients Treated for Hepatocellular Carcinoma"],"prefix":"10.1210","volume":"102","author":[{"given":"Carolien M","family":"Beukhof","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Academic Center for Thyroid Diseases, Erasmus University Medical Center, 3000 CA Rotterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leni","family":"van Doorn","sequence":"additional","affiliation":[{"name":"Erasmus MC Cancer Institute, Erasmus University Medical Center, 3000 CA Rotterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theo J","family":"Visser","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Academic Center for Thyroid Diseases, Erasmus University Medical Center, 3000 CA Rotterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sander","family":"Bins","sequence":"additional","affiliation":[{"name":"Erasmus MC Cancer Institute, Erasmus University Medical Center, 3000 CA Rotterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W Edward","family":"Visser","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Academic Center for Thyroid Diseases, Erasmus University Medical Center, 3000 CA Rotterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramona","family":"van Heerebeek","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Academic Center for Thyroid Diseases, Erasmus University Medical Center, 3000 CA Rotterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Folkert J","family":"van Kemenade","sequence":"additional","affiliation":[{"name":"Department of Pathology, Erasmus University Medical Center, 3000 CA Rotterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yolanda B","family":"de Rijke","sequence":"additional","affiliation":[{"name":"Department of Clinical Chemistry, Erasmus University Medical Center, 3000 CA Rotterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wouter W","family":"de Herder","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Academic Center for Thyroid Diseases, Erasmus University Medical Center, 3000 CA Rotterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Layal","family":"Chaker","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Academic Center for Thyroid Diseases, Erasmus University Medical Center, 3000 CA Rotterdam, Netherlands"},{"name":"Department of Epidemiology, Erasmus University Medical Center, 3000 CA Rotterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron H","family":"Mathijssen","sequence":"additional","affiliation":[{"name":"Erasmus MC Cancer Institute, Erasmus University Medical Center, 3000 CA Rotterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin P","family":"Peeters","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Academic Center for Thyroid Diseases, Erasmus University Medical Center, 3000 CA Rotterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2017,5,26]]},"reference":[{"key":"2019041118525089400_B1","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1089\/thy.2012.0456","article-title":"Tyrosine kinase inhibitor-induced thyroid disorders: a review and hypothesis","volume":"23","author":"Makita","year":"2013","journal-title":"Thyroid"},{"issue":"4","key":"2019041118525089400_B2","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"issue":"2","key":"2019041118525089400_B3","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"issue":"9940","key":"2019041118525089400_B4","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"issue":"10","key":"2019041118525089400_B5","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1158\/1535-7163.MCT-08-0013","article-title":"Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling","volume":"7","author":"Wilhelm","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"2019041118525089400_B6","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1089\/thy.2010.0234","article-title":"Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma","volume":"21","author":"van Doorn","year":"2011","journal-title":"Thyroid"},{"issue":"16","key":"2019041118525089400_B7","doi-asserted-by":"crossref","first-page":"e262","DOI":"10.1200\/JCO.2012.46.7142","article-title":"Case of sorafenib-induced thyroid storm","volume":"31","author":"Haraldsdottir","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019041118525089400_B8","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1177\/1756283X15618129","article-title":"Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib","volume":"9","author":"Granito","year":"2016","journal-title":"Therap Adv Gastroenterol"},{"issue":"9","key":"2019041118525089400_B9","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/jnci\/djr128","article-title":"Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib","volume":"103","author":"Rini","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"2019041118525089400_B10","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/cncr.25422","article-title":"Hypothyroidism in patients with renal cell carcinoma: blessing or curse?","volume":"117","author":"Schmidinger","year":"2011","journal-title":"Cancer"},{"issue":"2","key":"2019041118525089400_B11","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/annonc\/mdm483","article-title":"Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib","volume":"19","author":"Tamaskar","year":"2008","journal-title":"Ann Oncol"},{"issue":"7","key":"2019041118525089400_B12","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.ejca.2012.01.036","article-title":"Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: a cohort study","volume":"48","author":"Feldt","year":"2012","journal-title":"Eur J Cancer"},{"issue":"6","key":"2019041118525089400_B13","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00345-010-0627-2","article-title":"Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib","volume":"29","author":"Riesenbeck","year":"2011","journal-title":"World J Urol"},{"issue":"5","key":"2019041118525089400_B14","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.urolonc.2009.08.011","article-title":"Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: a prospective evaluation","volume":"28","author":"Miyake","year":"2010","journal-title":"Urol Oncol"},{"issue":"8","key":"2019041118525089400_B15","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/jjco\/hys076","article-title":"Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma","volume":"42","author":"Daimon","year":"2012","journal-title":"Jpn J Clin Oncol"},{"issue":"8","key":"2019041118525089400_B16","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1210\/jc.2009-2507","article-title":"Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination","volume":"95","author":"Abdulrahman","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2019041118525089400_B17","first-page":"86","article-title":"Thyroid hormone inactivation in gastrointestinal stromal tumors","volume":"371","author":"Maynard","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"2019041118525089400_B18","doi-asserted-by":"crossref","first-page":"E100","DOI":"10.1210\/jc.2011-1837","article-title":"Tyrosine kinase inhibitors noncompetitively inhibit MCT8-mediated iodothyronine transport","volume":"97","author":"Braun","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"35","key":"2019041118525089400_B19","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.4254\/wjh.v8.i35.1541","article-title":"How to assess the efficacy or failure of targeted therapy: deciding when to stop sorafenib in hepatocellular carcinoma","volume":"8","author":"Raoul","year":"2016","journal-title":"World J Hepatol"},{"key":"2019041118525089400_B20","unstructured":"U.S. Department of Health and Human Services. Common terminology criteria for adverse events v4.0. National Institutes of Health, Bethesda, MD."},{"issue":"3","key":"2019041118525089400_B21","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1210\/jcem-69-3-552","article-title":"Serum triiodothyronine sulfate in man measured by radioimmunoassay","volume":"69","author":"Eelkman Rooda","year":"1989","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2019041118525089400_B22","doi-asserted-by":"crossref","first-page":"6403","DOI":"10.1210\/jc.2005-0872","article-title":"Thyroid hormone concentrations, disease, physical function, and mortality in elderly men","volume":"90","author":"van den Beld","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2019041118525089400_B23","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1159\/000365191","article-title":"Psychomotor retardation caused by a defective thyroid hormone transporter: report of two families with different MCT8 mutations","volume":"82","author":"An\u0131k","year":"2014","journal-title":"Horm Res Paediatr"},{"issue":"2","key":"2019041118525089400_B24","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1210\/en.2013-1521","article-title":"The role of Arg445 and Asp498 in the human thyroid hormone transporter MCT8","volume":"155","author":"Groeneweg","year":"2014","journal-title":"Endocrinology"},{"issue":"8","key":"2019041118525089400_B25","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1210\/jc.2005-0535","article-title":"Serum 3,3\u2032,5\u2032-triiodothyronine (rT3) and 3,5,3\u2032-triiodothyronine\/rT3 are prognostic markers in critically ill patients and are associated with postmortem tissue deiodinase activities","volume":"90","author":"Peeters","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041118525089400_B26","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc Ser A Stat Soc"},{"issue":"7","key":"2019041118525089400_B27","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1210\/jc.2002-022013","article-title":"Reduced activation and increased inactivation of thyroid hormone in tissues of critically ill patients","volume":"88","author":"Peeters","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2019041118525089400_B28","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"2019041118525089400_B29","doi-asserted-by":"crossref","first-page":"660","DOI":"10.7326\/0003-4819-145-9-200611070-00008","article-title":"Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors","volume":"145","author":"Desai","year":"2006","journal-title":"Ann Intern Med"},{"issue":"5","key":"2019041118525089400_B30","first-page":"396","article-title":"Subacute (granulomatous) thyroiditis in Olmsted County, Minnesota","volume":"45","author":"Furszyfer","year":"1970","journal-title":"Mayo Clin Proc"},{"key":"2019041118525089400_B31","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1089\/thy.2012.0378","article-title":"Inappropriate elevation of serum thyrotropin levels in patients treated with axitinib","volume":"23","author":"Ohba","year":"2013","journal-title":"Thyroid"},{"issue":"1","key":"2019041118525089400_B32","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1210\/edrv-2-1-87","article-title":"Relationships between circulating and intracellular thyroid hormones: physiological and clinical implications","volume":"2","author":"Larsen","year":"1981","journal-title":"Endocr Rev"},{"issue":"Pt 2","key":"2019041118525089400_B33","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1042\/bj3290321","article-title":"Cloning and sequencing of four new mammalian monocarboxylate transporter (MCT) homologues confirms the existence of a transporter family with an ancient past","volume":"329","author":"Price","year":"1998","journal-title":"Biochem J"},{"issue":"10","key":"2019041118525089400_B34","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1210\/jc.2011-1172","article-title":"Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression","volume":"96","author":"Kappers","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041118525089400_B35","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1530\/EJE-12-0828","article-title":"Sorafenib therapy decreases the clearance of thyrotropin","volume":"168","author":"Verloop","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2019041118525089400_B36","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1210\/me.2012-1356","article-title":"Mutations in MCT8 in patients with Allan-Herndon-Dudley-syndrome affecting its cellular distribution","volume":"27","author":"Kersseboom","year":"2013","journal-title":"Mol Endocrinol"},{"issue":"3","key":"2019041118525089400_B37","doi-asserted-by":"crossref","first-page":"R67","DOI":"10.1530\/JOE-15-0133","article-title":"The molecular basis of the non-thyroidal illness syndrome","volume":"225","author":"de Vries","year":"2015","journal-title":"J Endocrinol"},{"issue":"6","key":"2019041118525089400_B38","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1210\/jc.2002-021592","article-title":"Polymorphisms in thyroid hormone pathway genes are associated with plasma TSH and iodothyronine levels in healthy subjects","volume":"88","author":"Peeters","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2019041118525089400_B39","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/hep.27399","article-title":"Local hypothyroidism favors the progression of preneoplastic lesions to hepatocellular carcinoma in rats","volume":"61","author":"Frau","year":"2015","journal-title":"Hepatology"},{"issue":"11","key":"2019041118525089400_B40","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1517\/14728222.2013.833189","article-title":"Type 3 deiodinase and solid tumors: an intriguing pair","volume":"17","author":"Dentice","year":"2013","journal-title":"Expert Opin Ther Targets"}],"container-title":["The Journal of Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/102\/8\/2922\/19452616\/jc.2016-4025.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T11:02:02Z","timestamp":1719226922000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/102\/8\/2922\/3852680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,26]]},"references-count":40,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2017,5,26]]},"published-print":{"date-parts":[[2017,8,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2016-4025","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,8,1]]},"published":{"date-parts":[[2017,5,26]]}}}